1 / 33

ASSESMENT OF PULMONARY THROMBOEMBOLISM PATIENTS DIAGNOSED IN OUR CLINIC A. Şimşek , G.Ö. Türkkan, K. Melek F.Ö.Eyüboğlu

ASSESMENT OF PULMONARY THROMBOEMBOLISM PATIENTS DIAGNOSED IN OUR CLINIC A. Şimşek , G.Ö. Türkkan, K. Melek F.Ö.Eyüboğlu. University of Baskent, Department of Chest Disease. INTRODUCTION.

levia
Download Presentation

ASSESMENT OF PULMONARY THROMBOEMBOLISM PATIENTS DIAGNOSED IN OUR CLINIC A. Şimşek , G.Ö. Türkkan, K. Melek F.Ö.Eyüboğlu

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASSESMENT OF PULMONARY THROMBOEMBOLISM PATIENTS DIAGNOSED IN OUR CLINICA. Şimşek, G.Ö. Türkkan, K. Melek F.Ö.Eyüboğlu University of Baskent, Department of ChestDisease

  2. INTRODUCTION • Venous thromboemboli (VTE) is the third most common cardiovascular disease after the ischemic heart disease and stroke. • The risk of PTE increases with advanced age • It was seen in male and female with same ratio

  3. PULMONARY THROMBOEMBOLISM (PTE) • Annual incidence : 0.23-1.83/1000 • Mortality rate : • without treatment: 30 % • with treatment: 14.7 • Cause can not be identified at 19-47% • Recurrance: • First year: 7-8 % • After 8-10 years: 30 %

  4. Immobilization Malignancy Trauma Advanced age Cardiopulmonary dis. Surgery Previous VTE Obesity Cerebrovasculary disease OC usage RISK FACTORS FOR PTE ACQUIRED RISK FACTORS

  5. Antiphospholipid Antibody Synd Prothrombin 20210 A mut. Increased Lipoprotein A Methylentetrahydrofolate reductase mutation(?) RISK FACTORS GENETIC RISK FACTORS • Antithrombin III deff • Protein C defficiency • Protein S defficiency • FV Leiden mutation • Hyperhomocysteinemie

  6. AIM The aim of this study was to define risk factors for PTE, clinical characteristics, demographic data of subjects, diagnostic procedures, and treatment responses

  7. MATERIAL AND METHOD We retrospectively analysed data from 164 patients admitted to our clinic with PTE in our hospital between 2000 to 2005

  8. MATERIAL AND METHOD • Sex • Age • Risk factors • Symptoms • Thorax CT • Lower extremities venous doppler US

  9. MATERIAL AND METHOD • Severity of PTE • Drugs used for treatment • Mortality rate • Recurrance rate

  10. RESULTS • Female ratio : 55.5 % • Male ratio : 44.5 % • Mean Age : - Female : 69.3 ± 13.6 - Male : 62.7 ± 18.3 - General : 66.3 ± 16.1

  11. RESULTS • Risk factors for PTE were absent in 25.6% of patients (idiopathic)

  12. RISK FACTORS FOR PTE

  13. SURGERY TYPE

  14. MALIGNANCY

  15. SYMPTOMS

  16. SIGNS

  17. LOCALIZATION OF PTE

  18. SEVERITY OF PTE

  19. PRESENCE OF LOWER EXTREMİTES VENOUS THROMBUS The ratio of cardiac thrombus was 5.5 %

  20. DRUGS USED FOR TREATMENT

  21. FOLLOW UP

  22. DISCUSSION

  23. Most frequently seen risk factors • Immobilization • Surgery • Most frequently seen surgery Sugery to lower extremities

  24. RISK FACTORS FOR PULMONARY EMBOLISM

  25. MALIGNANCY RATES IN PULMONARY THROMBOEMBOLISM

  26. In this study; • Lung and rectum cancer rates were lower than other studies • Liver cancer rate was higher than other studies • Pancreas cancer was not seen anymore

  27. According to our study, all malignancies can cause PTE • Our hospital is a solid organ transplantation center, for that reason liver cancer rate might be found high

  28. Lower ext. thrombus rate • Cardiac thrombus rate Similar with literature Recurrance rate was higher than literature

  29. RECURRANCE RATE IN PULMONARY EMBOLISM

  30. The reason of high recurrance rate of PTE in our study may be associated with long term (5 year) follow up • Long term follow up is more informative than 6-12 months follow up in determining recurrance rate

  31. Mortality rate was lower than literature • Early diagnosis • Early treatment • Long term follow up Effective in determining low mortality rates

  32. MORTALITY RATES IN PULMONARY EMBOLISM

  33. RESULTS • In order to determine correct recurrance rates, 5 year follow up is necessary • Long term and near follow up may reduce mortality • In presence of malignancy, VTE should be kept in mind as a complication • Because of high rate of idiopathic PTE, hereditary thrombophylic factors should be searched in all patients

More Related